Lihlahisoa

Niacin (nicotinic acid) e le monotherapy e ka fokotsa kotsi ea lefu la vascular, empa mokhoa oa eona oa ts'ebetso o ntse o le likhang, 'me o ka' na oa se ke oa itšetleha ka liphello tsa ho fetola lipid.Niacin e sa tsoa bontšoa hore e ntlafatsa ts'ebetso ea ho qetela le ho tsosolosoa ha methapo ea mali, e ikemetseng ho lokisa dyslipidemia, mefuteng ea litoeba tsa kotsi ea methapo le lefu la metabolism.Joalo ka selelekela sa biosynthetic bakeng sa NAD(+), niacin e ka hlahisa melemo ena ea methapo ka likarabelo tse lipakeng tsa NAD(+)-, sirtuin (SIRT).Ntle le moo, niacin e ka sebetsa ka receptor ea eona, GPR109A, ho khothaletsa ts'ebetso ea ho qetela, leha lisele tsa endothelial li sa tsejoe ho hlahisa mokelikeli ona.Re nahana hore niacin e ntlafatsa ka ho toba ts'ebetso ea lisele tsa endothelial nakong ea ho pepesehela maemo a lipotoxic 'me ra batla ho tseba hore na ho ka etsahala'ng (s) mokhoa o amehang.Angiogenic palmitate e feteletseng e ile ea hlahlojoa ka ho thehoa ha tube ka mor'a ho phekoloa ha lisele tsa "microvascular endothelial" tsa motho (HMVE C) le khatello e batlang e le tlase ea niacin (10 μM), kapa nicotinamide mononucleotide (NMN) (1 μM), selelekela sa NAD(+) se tobileng.Le hoja ka bobeli niacin le NMN li ntlafalitse sebopeho sa li-tube tsa HMVEC nakong ea boima ba palema, ke NMN feela e ileng ea eketsa tšebetso ea cellular NAD (+) le SIRT1.Hape re hlokometse hore HMVEC e hlahisa GRP109A.Ts'ebetso ea receptor ena e nang le acifran kapa MK-1903 e entsoeng ke niacin hape ka ntlafatso ea tlhahiso ea li-tube tsa HMVEC, athe GPR109A siRNA e ile ea fokotsa phello ea niacin. +) biosynthesis le ts'ebetso ea SIRT1, empa ho fapana le moo ka ts'ebetso ea niacin receptor.